Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

CULLINAN THERAPEUTICS, INC. (CGEM) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

CULLINAN THERAPEUTICS, INC. (CGEM), most recent 12 months reported: net loss $204.69M, free cash flow -$175.8M. Latest balance sheet on file: liquid cash $334.54M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): Black Hawk Acquisition Corporation · CABALETTA BIO, INC. · CANDEL THERAPEUTICS, INC. · CERO THERAPEUTICS HOLDINGS, INC. · Cognition Therapeutics, Inc. · Calidi Biotherapeutics, Inc. · COMPASS THERAPEUTICS, INC. · MOSAIC IMMUNOENGINEERING, INC.

Stock screener

Watchlist